Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2021-03-05 Board/Management Inform…
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document text contains details about the resignation of a CFO and KMP (Key Managerial Personnel) and the appointment of a new CFO and KMP, including dates and brief profiles. This is an announcement of changes in the company's senior management. There are no financial statements or detailed financial data, so it is not an annual or interim report. The content fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, confirming the classification.
2021-03-05 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document text contains details about the resignation of a CFO and KMP (Key Managerial Personnel) and the appointment of a new CFO and KMP, including dates and brief profiles. This is an announcement of changes in the company's senior management. There are no financial statements or detailed financial data, so it is not an annual or interim report. It is not a regulatory filing or other category. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, confirming this classification.
2021-03-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is a company announcement about the launch of a new branded generic drug product, Adsunib, and other oncology products. It discusses product details, market positioning, and future plans for product launches. There is no indication of financial data, regulatory filings, meeting materials, voting results, or any formal report structure. The content is promotional and informational about product launches and company strategy in oncology. Given the nature of the text, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2021-02-17 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a notification of the outcome of a Board Meeting held on 27th January 2021 by Beta Drugs Limited. It reports the sad demise of the Chairman cum Managing Director and the subsequent appointment and promotion of other directors to senior management positions, subject to shareholder approval. The content focuses on management changes and does not contain financial statements or detailed financial performance data. The document is relatively short (3162 characters) and is an announcement of board decisions rather than a full report. Therefore, it fits the category of Board/Management Information (MANG).
2021-01-27 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a notification of the outcome of a Board Meeting held on 27th January 2021 by Beta Drugs Limited. It reports the sad demise of the Chairman cum Managing Director and the subsequent appointment and promotion of other directors to leadership positions, subject to shareholder approval. The content focuses on management changes and board decisions rather than financial results, audit information, or regulatory filings. The document is relatively short (3162 characters) and is a formal announcement of board-level changes. Therefore, it fits the category of Board/Management Information (MANG).
2021-01-27 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (74 characters) and contains no substantive content, only placeholders and an omitted picture note. There is no financial data, report title, regulatory references, or any meaningful text to classify as a specific report type. Given the lack of content, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2020-11-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.